Catalyst

Slingshot members are tracking this event:

Regeneron (REGN) and Sanofi (SNY) Announce Phase 3 SARIL-RA-MONARCH Results Evaluating Sarilumab Compared to AbbVie's (ABBV) Humira in Rheumatoid Arthritis (RA)

Source Link:
http://files.shareholder.com/downloads/REGN/3112949479x0x917761/0CA2F06B-2F28-43FD-8B6C-E8A405E971E6/REGN_News_2016_11_16_General_Releases.pdf

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ABBV
100%
REGN
100%
SNY
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Nov 16, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Saril-ra-monarch, Sarilumab, Humira, Rheumatoid Arthritis, Adult Patients
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.